275 related articles for article (PubMed ID: 22652058)
1. Noradrenergic antidepressants increase cortical dopamine: potential use in augmentation strategies.
Masana M; Castañé A; Santana N; Bortolozzi A; Artigas F
Neuropharmacology; 2012 Sep; 63(4):675-84. PubMed ID: 22652058
[TBL] [Abstract][Full Text] [Related]
2. Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice.
Deltheil T; Guiard BP; Cerdan J; David DJ; Tanaka KF; Repérant C; Guilloux JP; Coudoré F; Hen R; Gardier AM
Neuropharmacology; 2008 Nov; 55(6):1006-14. PubMed ID: 18761360
[TBL] [Abstract][Full Text] [Related]
3. Mirtazapine-induced corelease of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex.
Devoto P; Flore G; Pira L; Longu G; Gessa GL
Eur J Pharmacol; 2004 Mar; 487(1-3):105-11. PubMed ID: 15033381
[TBL] [Abstract][Full Text] [Related]
4. Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation.
Nakayama K; Sakurai T; Katsu H
Brain Res Bull; 2004 Apr; 63(3):237-41. PubMed ID: 15145142
[TBL] [Abstract][Full Text] [Related]
5. Neurochemical interaction between dopaminergic and noradrenergic neurons in the medial prefrontal cortex.
Pan WH; Yang SY; Lin SK
Synapse; 2004 Jul; 53(1):44-52. PubMed ID: 15150740
[TBL] [Abstract][Full Text] [Related]
6. Noradrenergic terminals are the primary source of α
Devoto P; Flore G; Saba P; Scheggi S; Mulas G; Gambarana C; Spiga S; Gessa GL
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 90():97-103. PubMed ID: 30472147
[TBL] [Abstract][Full Text] [Related]
7. Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex.
Linnér L; Endersz H; Ohman D; Bengtsson F; Schalling M; Svensson TH
J Pharmacol Exp Ther; 2001 May; 297(2):540-6. PubMed ID: 11303041
[TBL] [Abstract][Full Text] [Related]
8. In vivo potentiation of reboxetine and citalopram effect on extracellular noradrenaline in rat brain by α2-adrenoceptor antagonism.
Ortega JE; Fernández-Pastor B; Callado LF; Meana JJ
Eur Neuropsychopharmacol; 2010 Nov; 20(11):813-22. PubMed ID: 20813509
[TBL] [Abstract][Full Text] [Related]
9. Noradrenaline reuptake inhibition enhances the antipsychotic-like effect of raclopride and potentiates D2-blockage-induced dopamine release in the medial prefrontal cortex of the rat.
Linnér L; Wiker C; Wadenberg ML; Schalling M; Svensson TH
Neuropsychopharmacology; 2002 Nov; 27(5):691-8. PubMed ID: 12431844
[TBL] [Abstract][Full Text] [Related]
10. Selective enhancement of mesocortical dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia.
Masana M; Bortolozzi A; Artigas F
Int J Neuropsychopharmacol; 2011 Feb; 14(1):53-68. PubMed ID: 20701825
[TBL] [Abstract][Full Text] [Related]
11. A combination of mirtazapine and milnacipran augments the extracellular levels of monoamines in the rat brain.
Yamauchi M; Imanishi T; Koyama T
Neuropharmacology; 2012 Jun; 62(7):2278-87. PubMed ID: 22342987
[TBL] [Abstract][Full Text] [Related]
12. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus.
Li Z; Huang M; Prus AJ; Dai J; Meltzer HY
Brain Res; 2007 Feb; 1134(1):70-8. PubMed ID: 17207474
[TBL] [Abstract][Full Text] [Related]
13. On the mechanism of antidepressant-like action of berberine chloride.
Kulkarni SK; Dhir A
Eur J Pharmacol; 2008 Jul; 589(1-3):163-72. PubMed ID: 18585703
[TBL] [Abstract][Full Text] [Related]
14. Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise.
Russo-Neustadt AA; Alejandre H; Garcia C; Ivy AS; Chen MJ
Neuropsychopharmacology; 2004 Dec; 29(12):2189-99. PubMed ID: 15199375
[TBL] [Abstract][Full Text] [Related]
15. Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats.
Dekeyne A; Gobert A; Iob L; Cistarelli L; Melon C; Millan MJ
Psychopharmacology (Berl); 2001 Nov; 158(2):213-8. PubMed ID: 11702096
[TBL] [Abstract][Full Text] [Related]
16. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
[TBL] [Abstract][Full Text] [Related]
17. R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum.
Ichikawa J; Meltzer HY
J Pharmacol Exp Ther; 1999 Dec; 291(3):1227-32. PubMed ID: 10565846
[TBL] [Abstract][Full Text] [Related]
18. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: II. A behavioral, neurochemical, and electrophysiological characterization.
Dekeyne A; Brocco M; Loiseau F; Gobert A; Rivet JM; Di Cara B; Cremers TI; Flik G; Fone KC; Watson DJ; Papp M; Sharp T; Serres F; Cespuglio R; Olivier B; Chan JS; Lavielle G; Millan MJ
J Pharmacol Exp Ther; 2012 Mar; 340(3):765-80. PubMed ID: 22178753
[TBL] [Abstract][Full Text] [Related]
19. Hippocampal and prefrontal dopamine D1/5 receptor involvement in the memory-enhancing effect of reboxetine.
De Bundel D; Femenía T; DuPont CM; Konradsson-Geuken Å; Feltmann K; Schilström B; Lindskog M
Int J Neuropsychopharmacol; 2013 Oct; 16(9):2041-51. PubMed ID: 23672849
[TBL] [Abstract][Full Text] [Related]
20. Effects of acute and chronic reboxetine treatment on stress-induced monoamine efflux in the rat frontal cortex.
Page ME; Lucki I
Neuropsychopharmacology; 2002 Aug; 27(2):237-47. PubMed ID: 12093597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
